Fierce Pharma

MAY 7, 2024

Even after consumer outfit Kenvue split from Johnson & Johnson one year ago, the company has been performing certain services for the pharma and medtech giant as part of a transition process. | Kenvue’s board of directors on Monday approved a plan to cut 4% of the company’s global workforce. The J&J spinoff employed about 23,000 staffers at the end of last year, so the layoff initiative could affect some 920 workers.

Pharma 288

Pharma 288

MedCity News

MAY 7, 2024

There is a growing urgency for alternative solutions that support consumers where they are, and this is where the promise of digital health can be transformative. The post Tech-Driven Healthcare: Paving the Way for Scalable Solutions appeared first on MedCity News.

Healthcare 123

Healthcare Healthcare 123

Fierce Pharma

MAY 7, 2024

In its opening months, after spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab). | After spinning off as a separate business from Novartis, Sandoz is riding the wave of a strong launch of its biosimilar version of AbbVie’s Humira (adalimumab). With Hyrimoz leading the way, sales of the company’s biosimilars reached $623 million in the first three months of this year.

Leads 253

Leads Sales 253

MedCity News

MAY 7, 2024

More than a third of employers are integrating accountable care into their health benefits, according to a new report from the Milken Institute. However, there are several barriers. The post Report: More Employers Are Looking To Deploy Value-Based Care appeared first on MedCity News.

122

122

Advertisement

Distribution

Fierce Pharma

MAY 7, 2024

While cystic fibrosis has long been Vertex Pharmaceuticals’ bread and butter, the company has been eager to diversify its revenue base in recent years. | As of mid-April, Vertex said it had collected 5 patients' cells for eventual treatment with sickle cell disease therapy Casgevy. That puts Vertex ahead of its gene therapy rival bluebird bio, which recently said it had collected just one patient's cells for its own SCD treatment Lyfgenia.

Pharmaceutical 239

Pharmaceutical Patients 239

MedCity News

MAY 7, 2024

Geneoscopy received approval for its noninvasive colorectal cancer screening test, which the FDA designated as a breakthrough device. This marks only the second time the FDA has issued an approval for a molecular diagnostic test for colorectal cancer — and the first time the agency has done so for a colorectal cancer test that uses RNA. The post FDA Grants First-Ever Approval to an RNA-Based Diagnostic for Colorectal Cancer appeared first on MedCity News.

FDA 103

FDA Biopharma 103

pharmaphorum

MAY 7, 2024

Understanding complex scientific studies is often a challenge for patients as well as healthcare professionals, but one that may become easier thanks to artificial intelligence.

Healthcare 96

Healthcare Healthcare Patients 96

Fierce Pharma

MAY 7, 2024

With $1.1 billion cash on | With $1.1 billion cash on Madrigal Pharmaceuticals’ balance sheet, CEO Bill Sibold believes the company can “fully resource” the launch of Rezdiffra, the first FDA-approved therapy for fatty liver disease.

FDA 171

FDA Pharmaceutical 171

pharmaphorum

MAY 7, 2024

Pfizer has paused dosing in a study of its Duchenne muscular dystrophy gene therapy after a sudden patient death in another trial

Patients 111

Patients 111

Pharmaceutical Technology

MAY 7, 2024

AstraZeneca has concluded an equity investment in clinical-stage biotechnology company Cellectis following a deal signed in November 2023.

96

96

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

pharmaphorum

MAY 7, 2024

Two-year data from a phase 1/2 trial of eyeDNA Therapeutics' gene therapy for retinitis pigmentosa sets up pivotal trials, says the new biotech.

90

90

Pharmaceutical Technology

MAY 7, 2024

A new study has further supported psilocybin's potential to treat depression, which impacts around 300 million people globally.

98

98

MedCity News

MAY 7, 2024

This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision making via elevated awareness. With the right tools in place, organizations can expedite strategic achievement across every area of the system. The post Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience appeared first on MedCity News.

Patients 81

Patients 81

PharmaTimes

MAY 7, 2024

The chronic brain disease that causes seizures currently affects around 600,000 people living in the UK

Patients 104

Patients 104

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Pharmaceutical Commerce

MAY 7, 2024

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages.

Pharma 103

Pharma 103

European Pharmaceutical Review

MAY 7, 2024

A novel intravesical targeted drug delivery system for patients with bladder cancer has demonstrated positive data in updated results from a Phase I trial. Johnson & Johnson’s Phase I study is assessing the safety and efficacy of TAR-210 as a delivery method for sustained, local release of erdafitinib into the bladder. The treatment is being evaluated in patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.

Food and Drug Administration 76

Food and Drug Administration Food Patients Safety 76

PharmaTimes

MAY 7, 2024

The rare and fatal progressive neurodegenerative disease is estimated to affect 5,000 people in the UK

88

88

European Pharmaceutical Review

MAY 7, 2024

Two new formulations cabotegravir (cabotegravir extended-release injectable suspension and tablets) have been approved by the Medicines and Healthcare products Regulatory Agency ( MHRA ). The treatment consists of Apretude 30mg film-coated tablets and Apretude 600mg prolonged-release suspension for injection. These treatments are indicated for the prevention of sexually transmitted HIV-1 infection — pre-exposure prophylaxis (PrEP) in adults and adolescents weighing at least 35kg with a higher in

Medicine 76

Medicine Healthcare Healthcare Pharmaceutical 76

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

pharmaphorum

MAY 7, 2024

Having two copies of the ApoE4 gene is not just a risk factor for the development of Alzheimer’s, but is a likely cause of the disease, according to researchers in Spain

70

70

European Pharmaceutical Review

MAY 7, 2024

A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 percent compound annual growth rate (CAGR) between 2024 to 2029. The market is anticipated to value $1139.4 billion by 2029. Injectable drugs are adopted widely as treatments for chronic infections such as HIV/AIDS and tuberculosis (TB). Treatment approaches for the latter condition is often a combination of oral antibiotics plus injectable drugs such as rifampin, isoniazid, and streptomyci

Food and Drug Administration 68

Food and Drug Administration Marketing Government Food 68

pharmaphorum

MAY 7, 2024

GSK commits to further support of BioVersys’ TB drug Phil.

103

103

Pharmaceutical Technology

MAY 7, 2024

The FTC is cracking down on pharma companies filing sham patents in the Orange Book to delay generics competition.

Pharma 78

Pharma Competition 78

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

Eversana Intouch

MAY 7, 2024

Asking yourself “what if” can provide a surge of energy to your thoughts – a mental supercharger, if you will. In this blog post, we’ll explore how these two words can not only transform your perspective, but also supercharge your brand plan. What does it mean to ask yourself “what if”? The idea comes from a curiosity to try something new, inspirational, bold or exciting.

Marketing 59

Marketing Pharma Healthcare Healthcare 59

PharmaVoice

MAY 7, 2024

The director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine believes the industry is “turning a corner.

Medicine 64

Medicine 64

Pharmaceutical Commerce

MAY 7, 2024

The latest news for pharma industry insiders.

Pharma 105

Pharma 105

LEVO Health

MAY 7, 2024

Healthcare organizations are increasingly partnering with influencers to build trust with their audience and expand their reach. By collaborating with influencers, healthcare brands can share their message with humanity, connect with consumers personally, and establish credibility within their target communities. Additionally, this marketing avenue helps practices and healthcare providers create meaningful patient relationships, foster loyalty, and drive business growth.

Healthcare 52

Healthcare Healthcare Marketing Healthcare Provider 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

PharmExec

MAY 7, 2024

In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, discusses how more granular insights into channel, tracing, and chargeback data can help drugmakers make smarter provider and payer contracting decisions.

Pharma 52

Pharma Pharmaceutical 52

Pharmacy Times

MAY 7, 2024

As pharmacy practice continues to evolve, it is imperative to recognize the vital contributions of all members of the pharmacy team, including pharmacy technicians.

62

62

PharmExec

MAY 7, 2024

The catheters approved by the FDA include the Plato 17, a DMSO-compatible microcatheter, and the Socrates 38, an aspiration catheter specifically designed for treating ischemic strokes.

FDA 52

FDA 52

Pharmaceutical Technology

MAY 7, 2024

Gossamer Bio and Chiesi signed a partnership and licence agreement aimed at developing and marketing seralutinib for pulmonary hypertension.

Marketing 52

Marketing 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management